search

Active clinical trials for "Neoplasms"

Results 3721-3730 of 64586

Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients...

Glioblastoma

The main objective of this clinical study is to evaluate the safety and tolerability of NK-92/5.28.z and to determine the maximum tolerated dose or maximum feasible dose (MFD). Recommended phase 2 doses both for intraoperative injections only (RP2Diio) and repetitive injections (RP2Dri) will be determined. Frequent side effects and target organs of toxicity and their severity, duration and reversibility will be determined. Furthermore, pharmacokinetics and pharmacodynamics will be examined. In addition, potential signs of anti-tumor activity of NK-92/5.28.z cells will be analyzed. In the separate "CAR2BRAIN-Check" cohort, combination therapy of NK-92/5.28.z with the anti-PD-1 antibody Ezabenlimab (BI 754091) will be tested.

Recruiting34 enrollment criteria

Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

ChemotherapyAdjuvant4 more

Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.

Recruiting22 enrollment criteria

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent...

Glioblastoma Multiforme

The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).

Recruiting106 enrollment criteria

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Head and Neck Squamous Cell CarcinomaCancer18 more

The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).

Recruiting34 enrollment criteria

The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular...

Hepatocellular Carcinoma

To compare the impact on survival of neo-adjuvant TAI for patients with HCC and PVTT who underwent hepatectomy.

Recruiting18 enrollment criteria

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer...

Advanced Bladder CarcinomaAdvanced Genitourinary System Carcinoma4 more

This phase II trial studies how well olaparib works in treating patients with bladder cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing.

Recruiting54 enrollment criteria

Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors

Thyroid CancerSalivary Gland Cancer

Phase II, 2-cohort, single arm trial treated with the combination of the following two agents: Pembrolizumab (MK3475) 200mg, every three weeks, iv Docetaxel 75mg/m2, every three weeks, iv

Recruiting39 enrollment criteria

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

Follicular Lymphoma

This research study is studying a novel type of FL vaccine as a possible treatment for follicular lymphoma (FL). The agents involved in this study are: Rituximab Personalized NeoAntigen vaccine Poly-ICLC Pembrolizumab

Recruiting44 enrollment criteria

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line...

DLBCL

Patients with CD30 positive DLBCL, primary refractory or in first relapse after R-CHOP or R-CHOP-like therapy will receive brentuximab vedotin in combination with R-DHAP, followed in responsive patients by high dose chemotherapy and ASCT.

Recruiting49 enrollment criteria

MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia (AML)

This is a dose-escalation phase I trial to evaluate the safety and tolerability of MAX-40279 in subjects with acute myelogenous leukemia(AML).

Recruiting33 enrollment criteria
1...372373374...6459

Need Help? Contact our team!


We'll reach out to this number within 24 hrs